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Abstract
Increasingly complex in silico modeling approaches offer a way to simultaneously access
cancerous processes at different spatio-temporal scales. High-level models, such as those
based on partial differential equations, are computationally affordable and allow large tumor
sizes and long temporal windows to be studied, but miss the discrete nature of many key
underlying cellular processes. Individual-based approaches provide a much more detailed
description of tumors, but have difficulties when trying to handle full-sized real cancers.
Thus, there exists a trade-off between the integration of macroscopic and microscopic infor-
mation, now widely available, and the ability to attain clinical tumor sizes. In this paper we
put forward a stochastic mesoscopic simulation framework that incorporates key cellular
processes during tumor progression while keeping computational costs to a minimum. Our
framework captures a physical scale that allows both the incorporation of microscopic infor-
mation, tracking the spatio-temporal emergence of tumor heterogeneity and the underlying
evolutionary dynamics, and the reconstruction of clinically sized tumors from high-resolution
medical imaging data, with the additional benefit of low computational cost. We illustrate the
functionality of our modeling approach for the case of glioblastoma, a paradigm of tumor het-
erogeneity that remains extremely challenging in the clinical setting.
Author summary
Computer simulation based on mathematical models provides a way to improve the
understanding of complex processes in oncology. In this paper we develop a stochastic
mesoscopic simulation approach that incorporates key cellular processes while keeping
computational costs to a minimum. Our methodology captures the development of tumor
heterogeneity and the underlying evolutionary dynamics. The physical scale considered
allows microscopic information to be included, tracking the spatio-temporal evolution of
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tumor heterogeneity and reconstructing clinically sized tumors from high-resolution
medical imaging data, with a low computational cost. We illustrate the functionality of the
modeling approach for the case of glioblastoma, an epitome of heterogeneity in tumors.
Introduction
Discrete mathematical models in cancer track and update individual cells according to a set of
biological rules as they interact with other cells and the microenvironment. There is a wide
variety of models of this type that include both on-lattice (such as cellular automata) and off-
lattice (agent-based) models. With the advent of single-cell resolution technology, next-gener-
ation sequencing techniques and the increasing availability of patient data, many mathematical
modeling efforts in oncology have been directed towards the use of discrete and individual-
based methodologies (see e.g. [1–4] for some reviews). These types of models are being used to
address a broad variety of cancer-related problems and some of them are even available as
open platforms for broad purpose simulation in cancer [5, 6].
However, discrete individual-based models also have some shortcomings. They typically
incorporate many parameters that have to be obtained from a limited amount of biological
information/data. Also, they are difficult to connect with imaging data, since medical imaging
has a limited spatial resolution of about 1 mm3. Although imaging techniques provide rough
information on tumor cell density, metabolic activity, vascular status, and other relevant vari-
ables, they do include the details of cellular dynamics within each voxel. Thus, there is room
for discrete cell-based modeling approaches beyond classical continuous ones based on partial
differential equations but working at the spatial scales at which tumor evolution can be
monitored.
From the computational point of view, individual-based models are computationally inten-
sive and suited to describing microscopic scenarios, in vitro experiments, or even small sec-
tions of tissues or model animals. Addressing human tumors in clinical stages normally
involves reducing the number of interactions, individuals or processes considered at the
microscopic levels, or representing them in a simpler manner. While awaiting progress in
computational power that allows for the inclusion of both detailed single cell information and
macroscopic simulated tumors, the choice of scale seems to be the dominant factor [7]. As has
recently been pointed out [8], few models are able to take into account three-dimensional
space, a broad mutational spectrum, mixing populations and reaching clinical or realistic sizes
in feasible computational time.
In this paper we put forward a three-dimensional, mesoscale, discrete, on-lattice, multi-
compartmental, stochastic approach intended to simulate biological phenomena in clinically-
sized tumors. The main element or agent is the cell subpopulation, whose definition is parallel
to how species are normally defined in ecological models [9]. Space is discretized in compart-
ments of adjustable size, which allows for comparison with medical imaging data. A compart-
ment is occupied by a number of cell subpopulations with different features, each undergoing
dynamics in its spatial location: growth, interaction with others and spatial spreading. This
intermediate scale allows for the integration of detailed biological data and for computationally
feasible simulations up to the macroscopic, whole-tumor scale.
The global evolution of the tumor is driven by the dynamics at each lattice position which,
in turn, is governed by the behavior of the different cell subpopulations, which are subject to
four fundamental biological processes: reproduction, death, mutation and migration. These
four processes, stemming from the basic hallmarks of cancer [10], occur stochastically in a
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synchronous manner, meaning that at each time step the population is updated according to
the probabilities computed in the previous step. As a result, the system moves from a very sim-
ple initial state to a fully grown, realistically sized, heterogeneous tumor, reconstructing its
entire natural history. Thus, the intent of this work is to present a computational framework to
study evolutionary dynamics of tumors. We provide an explanation of the functionality and
access to the codes. Owing to its low computational cost and simplicity, it allows for a compar-
ison with clinical information, revealing its potential applications in hypothesis generation
and testing.
As a bench test to assess our model’s performance and versatility in tumor modeling, we
also show a detailed application of the mesoscopic model to glioblastoma (GBM), one of the
most aggressive tumors, which also epitomizes intratumor heterogeneity and enhanced phe-
notypic adaptation capacity [11], with only approximately one in four patients alive two years
after diagnosis using current treatment modalities [12, 13]. By means of the TCGA genomic
characterization of GBM [14], information about the mutational spectrum of this tumor [15]
and the relative frequencies [16], coexistence [17] and exclusivity [18] is now available, some-
times including spatial information [19] and reconstructions of its evolutionary history [20,
21]. Imaging data is also increasingly available, providing valuable details related to geometry,
shape, size, regularity, and it is also used in biomarker identification [22–24]. It is therefore an
ideal scenario for testing and calibrating a model for tumor growth and diversification that
includes molecular information and reaches clinical sizes.
Materials and methods
Computational model
3D lattice. Space is discretized as a hexahedral mesh consisting of Lx × Ly × Lz spatial
units (voxels) or compartments, with Li being the number of compartments per spatial dimen-
sion. Both the volume and number of compartments in the grid are adjustable parameters.
Since high-resolution imaging (e.g. 3D magnetic resonance imaging T1/T2/FLAIR sequences)
voxel size is around 1 mm3, we chose that voxel size for the specific examples. No-flux bound-
ary conditions were set. However, we chose lattices large enough so that simulations will typi-
cally not reach the boundaries of the domain.
Clonal subpopulations. Each voxel contains cells that undergo different cellular pro-
cesses: division, migration, death and mutation. A cell belongs to a clonal subpopulation that
is defined by a set of traits. Traits are represented by a vector~g of length G,~g ¼ ðg1; g2; :::; gGÞ,
where G is the number of traits or alterations and gi can take the values 0 or 1. This value can
be interpreted as two possible expressions for a trait, or presence or absence of a mutation, as
typically done when treating species in ecological models [9]. The clonal subpopulation then
constitutes the basic unit or agent in the computational model, trading cell resolution for feasi-
ble simulation time and achieving clinical tumor sizes. The set of traits that represents a sub-
population determines the rate at which cells undergo biological processes, so that cells from a
given subpopulation on a given voxel will behave in the same way, except for stochastic noise
intrinsic to cell processes (biological instances of this are differential gene expression or vari-
able mitochondrial content). Populations with more advantageous traits will be more likely to
become fixed in the tumor, especially once they achieve a large cell number, whereas at early
stages (low cell numbers) genetic drift will be more important. The processes are modeled in
such a way that cells grow exponentially when there is enough empty space and slow their
growth as the voxel becomes crowded. Migration is also influenced by voxel occupation as
described below.
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System updating. In celular automaton and lattice gas models, the way in which the spa-
tial domain is updated can impact the outcome of the simulation. In [25], the authors dis-
cussed different manners of iterating through the grid. They recommended asynchronous
updating, drawing the time of event from an exponential distribution and randomly choosing
the lattice point to be updated. However, for processes with long timescales such as tumor
development, it is reasonable to replace this with synchronous updating with uniform time
step. In this manner, we compute the change in the population of each voxel according to the
state at time t, and then add these changes to obtain the state at t + 1. Thus, if we let Nx;y;zg;t be
the number of cells in subpopulation g at voxel (x, y, z) and time t, for g = 1, . . ., 2G and x = 1,
. . ., Lx, y = 1, . . ., Ly, z = 1, . . ., Lz, the number of cells at the discrete time t + 1 can be computed


















Eq (1) governs the updating of the cell number of each clonal population according to the
four basic cellular processes described above. It includes the positive contributions of newborn




cells in the same subpopulation migrating from other voxels in the neighborhood Mx;y;z of
current point, Nx
0 ;y0;z0
gmig;t . Cell numbers decrease by subtracting dead cells N
x;y;z
gdeath ;t, cells mutating to
different clonal subpopulations Nx;y;zgmut;t and cells migrating to surrounding voxels N
x;y;z
gmig;t. Each
process has an associated probability that depends on both local conditions and phenotype. A
cell attempting to undergo any of these processes may be regarded as a dichotomous event
with two possible outcomes: success (cell dividing, dying, migrating or mutating) or failure
(cell remaining still). Hence, each cell can be considered as a Bernoulli experiment. The way in
which the model is discretized allows us to assume that cells in the same voxel and subpopula-
tion will have the same probability. We can therefore update the whole clonal subpopulation
of a voxel by means of the binomial distribution, as it will give us the number of successes
from several Bernoulli trials (cells undergoing basic processes) that share the same probability.
The only exception is the mutation process: since its timescale is much longer than that of cell
division or death, mutations (being Bernoulli processes) are assumed to occur in individual




g;t ; PrepÞ; ð2aÞ
Nx;y;zgmig;t � BðA
x;y;z
g;t ; PmigÞ; ð2bÞ
Nx;y;zgdeath ;t � BðA
x;y;z
g;t ; PdeathÞ; ð2cÞ
Nx;y;zgmut ;t � BernoulliðPmutÞ: ð2dÞ
where Ax;y;zg;t represents the number of living cells in subpopulation g at voxel (x, y, z) and time t
and Prep, Pmig, Pdeath and Pmut denote the single cell probabilities of division, migration, death
and mutation, respectively. These probabilities are specified below. A summary of the updating
algorithm can be found in Fig 1. More details about the coding of the algorithm can be found
at the model’s Github repository (see ‘Software’).
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Cell division. Each clonal subpopulation has a different reproduction probability depend-










where Δt is the time step considered, A and D are the total active and necrotic population in
each voxel respectively and Nmax is the local carrying capacity. The probability is modulated by
the relationship between the time step and the characteristic time of the process; the probabil-
ity of a process to occur increases with the time step. The reproduction probability decreases
with occupation, simulating competition for space and resources. τrep is the part of the proba-
bility that depends on each subpopulation’s traits. It has units of time and is computed as
trep ¼ t
rep
0 ð1   ~wrep �~gÞ; ð4Þ
where the first term, t
rep
0 , is a basal reproduction time, assigned to the wild type, and the second
term represents how this basal rate is modified by the different alterations that the cell can
undergo. Also,~g is the trait vector and ~wrep ¼ ðw1;w2; :::;wGÞ, with wi representing the degree
to which an alteration modifies the respective rate. It satisfies |wi|< 1 and
PG
i wi < 1.
Cell migration. The migration process occurs in two differentiated steps. Firstly, the
number of cells leaving the current voxel is computed. They are then distributed into neigh-
boring voxels, taking into account their relative distances. The probability of migration for a








Fig 1. Algorithm. A) Basic algorithm (for implementation purposes). Initialization requires creating a 3D grid, specifying the final simulation time,
defining subpopulation traits and setting the initial state. Temporal iterations are then carried out until the end time is reached. At each time step and each
voxel, all clonal populations are updated. This updating involves calculating how many cells will proliferate, migrate, mutate or die. When all populations at
all voxels have been evaluated, they are updated synchronously. B) Two-dimensional example of model behavior. Synchronous updating results in
population increasing, diversifying and spreading at each time step, with probabilities computed according to the biological rules. Compartment color
indicates occupancy. Cell color indicates cell type. C) Bottom image is a slice of an actual simulation, with colors indicating occupation. Each voxel contains
a variable number of cells and subtypes as depicted above.
https://doi.org/10.1371/journal.pcbi.1008266.g001
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Eq (5) has a similar structure to the reproduction process in Eq (3) albeit the trait-dependent
term ρmig has the units of a diffusion coefficient (rather than being the inverse of a characteris-
tic time), and differs from the impact of each alteration on the process, encompassed by the
vector ~wmig. We include here the spatial step Δx, by analogy with the discrete Laplacian opera-
tor in space, in order to keep the probability adimensional. We calculate ρmig in the following









0 is a basal diffusion constant corresponding to the wild type modulated by subse-
quent alterations. Notice that the product between ~wmig and~g is moved to the denominator in
order to keep the same structure as in the other basic processes. In contrast with the reproduc-
tion probability, the migration probability increases with the occupation of the voxel, since a
cell is more likely to migrate if there is more competition for space and/or resources. Necrotic
cells do not migrate, but they do occupy space, and thus this is taken into account in (5).
As for the destination of each cell migrating from a voxel (x, y, z), we considered a Moore
neighborhood Mx;y;z in three spatial dimensions. In this way, each migrating cell has 26 possi-
ble destinations. In order to determine which neighbouring voxel receives which number of








depending on whether voxels share a face, edge or vertex with the central voxel
respectively. The distribution of migrating cells into each destination voxel is then computed
by sampling a multinomial distribution:
~Y � Mult ðX;~PMooreÞ
where ~Y is a vector of 26 components giving the number of cells that migrate to each voxel, X
is the number of migrating cells that has been previously computed according to Eq (2b) and
~PMoore is a vector of 26 components giving the probabilities of migration to each surrounding
voxel. Performing the migration in this way reproduces a diffusive process, in which migration
depends on cell density gradients and distances. To better illustrate migration, a scheme of the
process can be seen in S1 Appendix.
Cell mutation. Mutation is the mechanism that captures the diversification of the popula-
tion, and is considered here in a broad sense as a change in one of the characteristics of the









so that mutations depend only on A, the number of cells in a given subpopulation; Nmax, the
carrying capacity, and τmut, the characteristic time that includes trait effects as explained
above. This probability measures the chance of a mutational event occurring, not the specific
alteration; this is later randomly selected from a subset of the vector~g , representing non-
altered traits.
Cell death. The form of the cell-death term is similar to the proliferation term, with the
difference that the probability of death increases with occupation. The expression for the
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where τdeath is a typical cell lifetime. The reason for this dependence is that aggressive tumor
cells eventually induce a damage to the microenvironment that leads to their own death. In the
specific tumor type considered in this paper, GBM, it is well known that this happens through
the secretion of prothrombotic factors that promote microvessel failure and the formation of
necrotic areas [26].
Estimation of parameters
Since one of our goals is to apply the mesoscopic simulator to the case of GBM as a benchmark
test, we used the sizes typically found in the clinical setting for the tumor maximum sizes,
which are around 100-120 cm3. Hence, we selected L = 80 voxels per spatial length to make
these sizes attainable. The time step was fixed at 4 hours. From typical cell sizes [27] we esti-
mated the carrying capacity of a single voxel Nmax to be 2 × 105 cells.
Sequencing studies of GBMs [14, 16] reveal that most of the mutations found in this disease
cluster around three main pathways: RTK/PI3K/RAS, RB and p53. Each of these pathways has
different key alterations and frequencies. We therefore considered a set of three possible alter-
ations characterizing populations (G = 3), so that~g ¼ ðg1; g2; g3Þ. This means that there are
eight possible cell subtypes (2G), depending on all possible combinations of altered pathways
(Fig 2).
The choice of division, death, mutation and migration basal rates used a Bayesian criterion.
To obtain an initial coarse estimate of the parameter ranges, the most straightforward way is to
use imaging data from real GBMs. Basal reproduction and death rate (Table 1) were estimated
Fig 2. Mutation tree used in this paper. Relationships between the eight possible genotypes, according to the three
alterations selected. Each clonal type can emerge from several ancestors by various alterations. Depending on the
mutational history, tumors follow different paths on the mutation tree.
https://doi.org/10.1371/journal.pcbi.1008266.g002
Table 1. Parameter values for simulations of GBM. Basal rates refer to cells with no mutations. Weights specify how each mutation affects the basal rate.
Alteration Reproduction Migration Mutation Death
RTK 0.32 0.65 0.18 -0.15
RB 0.28 0.05 0.18 -0.05
p53 0.25 0.05 0.32 -0.45
Basal 80-250 h 0.0033-0.0125 mm2/h 80-240 h 80-400 h
https://doi.org/10.1371/journal.pcbi.1008266.t001
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from papers using exponential/gompertzian growth laws to fit GBM growth curves [28, 29].
Basal migration parameters were estimated from [29]. Since monitored tumors already carry
an unknown mixture of alterations, these numbers should be taken only as rough estimates.
Basal mutation rates were estimated from the known values per base and generation for each
altered pathway [30–32]. To refine those ranges, thousands of simulations were run with input
parameters randomly sampled from previous ranges. Simulations whose tumor lifespans were
substantially longer than those typical of real GBMs were rejected. Simulations whose tumor
lifespans were close to those of real GBMs were accepted. Basal rate ranges were thus con-
structed on input parameters from accepted simulations.
The next parameters to estimate are the mutation weights (wi). Namely, the effect that
alterations have on the rates at which cells perform basic cellular processes. Note that these
weights are different from the mutation rates. We estimated mutation weights on a qualita-
tive manner, based on the impact that alterations in considered pathways have over cell divi-
sion, death, migration and mutation. For instance, alterations in RTK/PI3K/RAS pathway
typically promote proliferation and migration. Cell cycle regulator p53 is mainly involved in
genome repair, thus its alterations promote death evasion, as well as increased genetic insta-
bility, which leads to a higher mutation rate [33]. RB is another regulator that prevents exces-
sive cell growth by inhibiting cell cycle progression, so alterations in its pathway will
influence division and death as well. We chose a set of weights based on this biological knowl-
edge, ensuring that clonal populations undergoing all mutations did not reach unrealistic
proliferation rates, and we stuck to this set for all simulations performed throughout this
study. The final choice of weights is shown in Table 1 as well as the chosen ranges for the val-
ues of the basal characteristic times. Notice that these times are associated with cellular pro-
cesses; whole-tumor rates emerge as a result of combined cellular processes. Cellular traits
were randomly sampled from the range of allowed basal rates for each simulation. This pro-
vided variability between individual simulations and allowed us to assess the robustness of
the model’s behavior.
Although the same set of mutation weights was used for all simulations, we assume that
there exists a set of N probability distributions, one for each mutation weight, such that the
alteration frequencies retrieved from in silico tumors resemble those of real tumors. To deepen
our knowledge about mutation weight distribution and to improve their estimation, we used a
simple version of Approximate Bayesian Computation (ABC) rejection algorithm [34] (see S2
Appendix). We run a number of simulations with a random sample of the mutational weights
and accepted those values whose respective in silico tumor had a mutational landscape similar
to that of real tumors [15, 16, 33, 35]. In this way, we can tune these weights to produce tumors
with realistic mutational contents. Alteration frequencies of in silico tumors were retrieved at
the time of diagnosis. We repeated this process with the posterior distribution until obtaining
a robust estimate for the distributions. Note that our choice of mutation weights (Table 1),
while being based on biological knowledge instead of ABC rejection algorithm, is pretty close
to the most likely value from probability distributions of mutation weights obtained by this
algorithm.
Macroscopic tumor measures
We will use a set of measures to quantitatively compare tumor longitudinal dynamics with the
solutions of the discrete simulation model. We list them here and give precise definitions.
Heterogeneity. Diversity indexes are used in ecology to track genotype heterogeneity
[36]. Two of the most frequently used are Shannon entropy and the Simpson index. The Shan-
non entropy quantifies the uncertainty in predicting the species of a selected individual in a
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piðtÞ log piðtÞ; ð9Þ















i¼1 Aiðx; y; z; tÞÞ
; ð10Þ
where Ai(x, y, z, t) is the number of active cells from species i in voxel (x, y, z) at time t. The






A Shannon entropy equal to 0 means that all cells in the system belong to the same subpop-
ulation, so there is no uncertainty in predicting cell type. A higher Shannon entropy means
higher uncertainty and thus higher heterogeneity. A Simpson index of 1 indicates that all cells
belong to the same type, while a value of 0 shows that there are no cells of equal type. In this
study we were interested in heterogeneity dynamics of the whole tumor, so we considered
Shannon entropy and the Simpson index integrated over all space, as functions of time. Using
these indexes we can infer whether several cell populations with different mutational profiles
coexist within the tumor, or a single cell population dominates over the others.
Volumetric and morphological measures. Let V be the set of voxels that have reached
more than 20% of their carrying capacity, considering both living and necrotic cells. Let VCE be
the subset of V consisting of voxels in which active cells alone have reached more than 20% of
the carrying capacity. Let VI be the complementary subset VI ¼ V n VCE. Let us define the
number of elements in each set by NCE ¼ jVCEj, NI ¼ jVIj and NT ¼ jVj. Note that, because of
this definition VCE \ VI ¼ ;. Then, if individual voxel volume is Vvox, we define the contrast-
enhancing (VCE) and inner or necrotic (VI) volumes as
VCE ¼ NCEVvox; ð12aÞ
VI ¼ NIVvox: ð12bÞ
Contrast-enhancing volume is associated with active tumor regions, while inner volume repre-
sents the necrotic core. Both quantities can be obtained from computer simulations of our
mathematical model. The sum of both magnitudes represents the whole tumor volume, V =
VCE + VI. The surface S enclosing V, and its measure S, were obtained using the marching
cubes method, seen in [24], to resemble the method used to extract this feature from MRIs.
We also defined the mean spherical radius (MSR), as the radius of a sphere having the same






In addition to the volumetric measures we also employed several morphological descriptors
that have been found to have prognostic value in different tumor types. They are active tumor
spherical rim width (δs) and surface regularity (Sreg). The first one is obtained from MRIs as an
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averaged distance between the contrast-enhancing volume and the necrotic core [37]. It can be










This biomarker has been found to have prognostic value for GBMs using both MRI [23, 37]
and PET [38] images.
To quantify the surface regularity we used a dimensionless ratio defined as the relation







The closer this ratio is to 1, the more similar to a sphere a tumor will be (more regular).
When Sreg approaches zero the tumor will be highly irregular, resembling a fractal-like struc-
ture. This parameter receives different names in the literature and has been found to have
prognostic value in lung cancer [39, 40], head and neck cancer [41, 42], esophageal cancer
[43], breast cancer [44], lymphoma [45], and glioma [24, 38].
Tumor growth law
The search for the mathematical equations that govern tumor growth has been a constant in
the history of mathematical oncology [46–48]. Several attempts have been made to fit tumor
growth laws to longitudinal volumetric data, including GBM [28, 49]. Here, we aim to repro-
duce this for the simulated tumors. We select exponential, gompertzian and radial growth, all
of which have been analyzed in the previously cited studies. Motivated by the morphological
analysis described above we also tried to fit to a power law, a variation of the von Bertalanffy
equation and another usual candidate for tumor growth law. The equations to be fitted are
therefore:
VðtÞ ¼ V0 exp ðatÞ; ð16aÞ
VðtÞ ¼ ð4p=3Þðr0 þ atÞ
3
; ð16bÞ
VðtÞ ¼ K exp ð log ðV0=KÞ exp ð  atÞÞ; ð16cÞ
VðtÞ ¼ ½V ð1  bÞ0   aðb   1Þt�
1=ð1  bÞ
; ð16dÞ
where V0 is initial volume and r0 the corresponding mean initial radius, α denotes respective
growth rates, K is the carrying capacity in the Gompertz model and β is the scaling exponent
in the power law (it is positive and can be greater than 1, see [50]). We used Matlab function
lsqcurvefit to obtain fitted parameters and root-mean-square error in order to compare
goodness of fit. Initial value was fixed to that of the simulated tumor and the carrying capacity
in the Gompertz model was assigned an upper bound of 1400 cm3 (average cranial capacity).
For the power law, we tried different scaling exponents β and selected the one providing the
best fit.
Survival analysis
The measures explained above have prognostic value in real GBMs. In order to compare in sil-
ico and real tumors, survival time has to be modeled in some way. Given the current state of
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the model, any definition of survival time will necessary be a simplification, since there are
many factors that influence prognosis and fatality that cannot all be taken into account here.
We follow other examples of survival analysis in mathematical models that use tumor size as
an indicator of fatality [51, 52]. There is also clinical evidence that points to this association
between prognosis and tumor size [53, 54].
We first define a diagnosis time. In order to do so, we have used data from 69 patients of
The Cancer Imaging Archive, diagnosed with GBM (data available in S1 Table). In a previous
work, these images were segmented and the total volumes computed [24]. We used these vol-
umes to construct an empirical distribution of diagnostic sizes. As an independent validation
of that empirical distribution, we also considered the patient data from [54]. There, it was
found, in a cohort of 209 GBM patients, that the median preoperative tumor volume was 24.9
cm3 (interquartile range 11.1-49.0 cm3). This range agrees with the one used by us for con-
structing the distribution of volume sizes at GBM diagnosis. In contrast, this same procedure
cannot be employed to retrieve a distribution for tumor volumes at patient’s death. Usually the
last available measure of tumor volume corresponds to the last follow-up, which differs from
the moment of death to some extent. Most importantly, any empirical distribution of tumor
volumes at the time of death would be biased by the treatment received by the patient. To
avoid these limitations, we seized the estimate of 6 cm of diameter (113 cm3) from [51, 52],
which is based on studies of GBM sizes at exitus. In order to take into account the potential
growth from the time of the last follow-up to decease, we select the range 100-120 cm3. Having
ranges of diagnostic and death sizes, we can assign a tumor lifespan to each simulation by sam-
pling from the respective distribution.
We then performed a Kaplan-Meier analysis over sets of simulations to evaluate the model’s
ability to reproduce prognostic values. Kaplan-Meier is a non-parametric statistic that is used
to estimate the survival function from a lifetime dataset. The survival function is a monotoni-
cally decreasing function that gives the probability of a patient/device’s survival beyond a spec-
ified time. It is defined as follows:
SðtÞ ¼ Pðt > tÞ; t � 0 ð17Þ
where τ is a random variable that represents the time that it takes for an event of interest to
occur. Provided that we know the set of times {τi} at which the event of interest took place for









where ti represents a time when at least one event took place, di is the number of events that
took place at time ti (death of a patient, in this context), and ni is the number of patients that
are still alive at time ti. As we have defined a survival time for each simulated tumor, we can
calculate the Kaplan-Meier statistic to estimate the survival curve of a set of simulations.
A splitting threshold was used to separate simulations into two groups, according to the
measures explained earlier in this section. The standard statistical test to compare Kaplan-
Meier estimators from different groups is the log-rank test. Time separation between curves at
median survival was also calculated. We performed a search over all possible splitting thresh-
olds and assessed significance of each of them, provided that the larger group was not more
than 3 times the size of the smaller group.
As survival time depends on random sampling of tumor volumes at diagnosis and at
patient’s death, we repeated this analysis 1000 times with different random seeds. Additionally,
we performed this survival analysis twice, using two different distributions of tumor volumes
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at death: a uniform distribution and a Gaussian one. In doing so we can check the effects that
the selected distribution has in the survival times obtained. The whole virtual survival analysis
is further detailed in S3 Appendix.
Software
The model was coded both in Matlab (R2018a, The MathWorks, Inc., Natick, MA, USA) and
Julia (version 1.1.1). The main workspace and simulation sections were coded in Julia, while
data analysis and plotting were coded in Matlab. Simulations were performed on three differ-
ent machines: a 12-core 32 GB RAM 2.7 GHz Mac Pro, a 6-core 16 GB RAM 3.7 GHz custom-
built computer, and a 2-core 8 GB 2 GHz MacBook Pro. Computational cost per simulation
was of the order of 3-5 minutes, depending on the machine used and the simulation parame-
ters. More details about code and visualization can be found in the Github repository of the
simulator (https://github.com/JuanJS117/MesoscopicModel).
Results
Until now, we presented the mesoscopic model as a new methodology for tumor growth simu-
lation at sizeable scale and in very short times. We now show in this section the functionality
of the model. As a form of validation, we compare the clinically-sized simulated tumors to vol-
umetric and morphological results of GBM. We also attempt to recover known evolutionary
features of cancer such as heterogeneity, fixation and dominance of aggressive clones.
Simulated tumors recapitulate known GBM timescales and resemble
clinical imaging data
To simulate the basics dynamics displayed by the model, we ran a set of 100 simulations start-
ing from one wild-type cell (i.e. without mutations) placed at the center of the spatial domain.
Each simulation had a different set of basal rates, sampled randomly from the ranges specified
in Table 1 as discussed previously. This allowed us to study variability in the tumor dynamics.
Tumors evolved according to the rules explained in the previous section and the volumetric,
morphological and metabolic macroscopic variables were tracked as discussed in the ‘Materials
and methods’ section. Results are shown in Fig 3. The range of basal rates considered allows
for the appearance of tumors with long inception (up to 10 months) as well as rapidly growing
cancers (less than 5 months combining inception and growth), both in terms of MSR (Fig 3E)
and volume (Fig 3F). These values are in agreement with clinical experience since treated
GBM patients have a median overall survival time of about 15 months [12].
The filling of a single voxel follows a dynamics resembling logistic growth. An initial fast-
growing phase is followed by a peak in the number of active cells, which begin to decline due
to saturation-induced death and migration to surrounding voxels (Fig 3B). While the total
number of cells (both active and necrotic) tends to the carrying capacity in the long term,
active cells decline to zero steadily as they die due to damage to the microenvironment. This
can be seen in Fig 3A, where newborn cells reach a peak in activity, early in growth, and then
decline steadily. The logistic-like dynamics within individual voxels does not imply that the
global growth of the tumor is also bounded. This is because the available physical space around
populated voxels allows for sustained growth in tumor volume (Fig 3C). We tried to fit this
sustained growth to different growth laws as explained in the ‘Materials and methods’ section
(Fig 3G). The best fit for the median run according to the RMSE corresponded to a power law
with scaling exponent of β = 1.21 (Fig 3H).
Since space is discretized in hexahedral units, and resolution is low for small tumors, vol-
ume and surface calculations are not precise until tumor cells have spread to a large group of
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voxels. For example, if a tumor occupying three voxels expands to a fourth voxel, this would
greatly distort its morphology, introducing fluctuations in morphological and geometrical
measures. This is shown in Fig 3D, and especially affects those measures that approximate the
tumor to a sphere (MSR, rim width, surface regularity). Because of this, tumor measures are
only reliable when tumor volume exceeds 1 cm3. Once this detectable size has been reached,
MSR behaves linearly up to a point where there is acceleration in growth, due to the appear-
ance and competition posed by more aggressive genotypes that increase the global growth rate.
This is more clearly seen in Fig 3F, which shows the evolution of the MSR along with three-
Fig 3. Longitudinal tumor growth dynamics. A) Time dynamics of the number of newborn cells at the central voxel (surrogate for tumor activity). B)
Number of cells at the central voxel: total (dashed red), active (blue) and necrotic (grey). C,D) Tumor volume and MSR during the initial stages, starting
from a single cell at the center of the lattice until tumor reaches 1 cm3. E) Dynamics of MSR for 100 simulations. Median run is shown in red. Time span
shown starts when tumor reaches 1 cm3 in volume (equivalent to 6.2 mm of MSR) and ends after reaching 100 cm3. F) Example of tumor dynamics of the
MSR and rendered 3D tumor shape for three different times (8.5, 10, 11.5 months). Basal rate parameters for simulation in this figure are τrep = 216.5 h,
τdeath = 112.7 h, τmut = 200.4 h, rmig ¼ 0:0081 mm2h . G) Dynamics of tumor volume for 100 simulations. Black lines represent different fits of the median run
(solid red line): Exponential (solid), power law with β = 1.2 (dotted), Gompertz (dashed) and radial (dashed-dotted). H) Root-mean-square error (RMSE)
of each fit.
https://doi.org/10.1371/journal.pcbi.1008266.g003
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dimensional reconstructions of the tumor for a typical run. The sharp increase in size occurs
during the last two months of the disease, in agreement with the known lethal progression of
these tumors [55].
Fig 4 shows two-dimensional slices of six simulated tumors, and one of a post-contrast pre-
treatment T1-weighted MRI scan of a GBM patient. In this type of image, white areas corre-
spond to regions where an intravenously injected gadolinium contrast is released into the tis-
sue. The reason is that tumor blood vessels are less stable and lack functional pericytes. Thus,
this marker is a surrogate of tumor cell density, leading to more abnormal vessels and suggest-
ing that brighter areas would correspond to higher tumor cell loads. However, above a certain
density, tumor cells damage the microenvironment and the secretion of prothrombotic factors
leads to massive local cell death [26]. Inner dark regions represent necrotic tumor areas calcu-
lated as explained in ‘Materials and methods’. The presence of a tumor-enhancing rim enclos-
ing a highly irregular shape, which is a characteristic hallmark of GBM, is also captured in our
simulations, and represents a region of highly proliferating cells [56].
Evolutionary dynamics showed development of heterogeneity and
dominance of the most aggressive clones
The simulator can be used to study the evolutionary dynamics within the tumor. An example
is shown in Fig 5A, which shows the three-dimensional reconstruction of the tumor at three
time points. In the first, the tumor mainly comprises the wild-type subpopulation, with small
contributions of early-arising subtypes containing only one mutation. At the second time
point we observe the emergence of more complex genotypes, with a significant contribution
from the RTK mutated type, due to the effect of this mutation on proliferation. The end time
point shows increased heterogeneity of the tumor with more altered genotypes taking over
most of the tumor surface. This leads to the appearance of explosive peripheral areas (also
resembling the lower parts of the tumor shown in Fig 4A). These features can be more clearly
Fig 4. Tumor slice and simulated profiles. A) Two-dimensional slice of a T1-weighted post-contrast MRI scan of an
actual GBM. B) Two-dimensional slices of different simulated tumors. Each simulated tumor corresponds to the final
state (100 cm3) of a different running of the model. Basal parameters for each simulation are: 1) τrep = 242.6 h, τdeath =
213.27 h, τmut = 221.6 h, rmig ¼ 0:0054 mm2h , 2) τ
rep = 206.7 h, τdeath = 90.5 h, τmut = 219.5 h, rmig ¼ 0:0044 mm2h , 3) τ
rep =
184.2 h, τdeath = 325.4 h, τmut = 186.5 h, rmig ¼ 0:0038 mm2h , 4) τ
rep = 233.5 h, τdeath = 143.0 h, τmut = 175.9 h,
rmig ¼ 0:0052 mm
2
h , 5) τ
rep = 201.2 h, τdeath = 295.5 h, τmut = 132.3 h, rmig ¼ 0:0048 mm2h , 6) τ
rep = 219.8 h, τdeath = 177.2
h, τmut = 87.33 h, rmig ¼ 0:0042 mm2h . Other parameters are listed in Table 1.
https://doi.org/10.1371/journal.pcbi.1008266.g004
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Fig 5. Example of the dynamics of the tumor’s clonal composition. A) Evolution of the eight clonal populations included in the model (one per
row). Total tumor volume is shown as a light blue background. Times correspond to 8.5, 10 and 11.5 months. Parameters for this simulation are
τrep = 179.1 h, τdeath = 292.5 h, τmut = 222.7 h, rmig ¼ 0:0071 mm2h . Other parameters are as in Table 1. B) Tumor central slice showing in white high
tumor cell density. C) Three-dimensional subtype composition of the tumor. D) Reconstruction of the phylogeny of the tumor. Each bifurcation
represents a mutation. Bifurcations occurring first in each branch represent mutations appearing earlier in time.
https://doi.org/10.1371/journal.pcbi.1008266.g005
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perceived in Fig 5B and 5C, a reconstruction of the whole tumor in its final stages. In this case
tumor diameter is around 7 cm, again in the range of real GBMs [29, 37]. It is important to
point out that the three-dimensional reconstructions are isosurfaces of the total volume occu-
pied by a subpopulation. There is overlapping, since two subpopulations or more can coexist
in a given region of the tumor, hence the superposition of colors seen in the reconstruction.
Fig 5D shows a phylogenetic reconstruction of the tumor. This is typically done in genetic
analysis of GBM [20, 21]. Here we show that it is possible in the model to track the time at
which a given mutation appeared and reconstruct from which population it came. Note that
phylogenetic tree reconstructions of clonal lineages for individual GBMs have been performed
by combining bulk exome sequencing with single-cell RNA-seq data [57].
As new clonal subpopulations appear in the tumor, heterogeneity is expected to increase.
However, due to cell competition and selection of the fittest, more aggressive subpopulations
may end up occupying all the available space, confining less aggressive subpopulations to the
core of the tumor and preventing them from proliferating, thus driving them to extinction.
This fixation effect may result in a decrease in heterogeneity, as the fittest subpopulation
becomes dominant. Fig 6A shows an example of the oscillatory behavior of the heterogeneity,
as measured by the Shannon and Simpson’s indexes. Changes in these indexes are associated
with proliferation of several subtypes or the dominance of one, respectively. This is more
clearly seen in Fig 6B, which depicts the abundance of each subtype on a logarithmic scale. In
this example simulation there is a clear increase in heterogeneity between months seven and
ten of the simulation, with the coexistence of the first four subtypes. The dominance of the
RTK subtype then causes heterogeneity to decrease, only to rise again with the appearance of
more complex genotypes. Expansions and extinctions seen in this figure are compatible with
the reconstructions shown in Fig 5A. Depending on when and where new clonal subpopula-
tions appear, each simulation will bring a different evolutionary dynamic. Often, the most
Fig 6. Dynamical behavior of tumor heterogeneity. A) Evolution of Shannon and Simpson’s indexes for a typical run. Basal rates for this run are τrep =
242.6 h, τdeath = 213.3 h, τmut = 221.6 h, rmig ¼ 0:0054 mm2h . The other parameters are those of Table 1. B) Abundance of each subtype in logarithmic scale as
a function of time. C) Superposition of final subtype abundance for all simulated tumors. D) Final abundance per subtype per simulation. Each row
corresponds to one subtype, in the same order as above. Color indicates end-point abundance.
https://doi.org/10.1371/journal.pcbi.1008266.g006
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aggressive population carrying all alterations prevails, but a coexistence of two or more sub-
populations may also take place. A combined view of the final state for all simulations is
shown in Fig 6C. The heatmap below (Fig 6D) displays a clearer view of the possible endpoints
of a simulation.
Surrogates of tumor growth obtained from the model replicate the
behavior of real GBMs
Much effort has been directed towards finding imaging-based prognostic biomarkers in GBM
[17, 23, 24, 37, 58–62]. Our simulations allow the whole tumor natural history to be recon-
structed, from its inception to the patient’s death. We focus our attention here on variables
that can be obtained from our simulations and that have been found to have a prognostic
value: Rim width, and surface regularity (See ‘Materials and methods’).
One of the most typical analyses in terms of prognostic value involves extracting the values
of these parameters from diagnostic images and correlating them with patient survival. In our
case, the model allows for tracking the evolution of these metrics over the whole tumor life-
span. Results for rim width and surface regularity for 100 simulations are shown in Fig 7. Time
units have been normalized in order to compare simulations with different ranges of time evo-
lution (see Fig 3). Curves represent the progression of the tumor from 1 cm3 to 100 cm3. Rim
width typically increased with time as the tumor became more aggressive. This is an important
difference with models having a simple clonal composition [56, 63], where the rim width was
found to be constant. However, both approaches led to the same conclusion, namely, that rim
width on diagnosis was associated with prognosis. Surface regularity was found to correlate
with tumor clonal composition. Tumor slices corresponding to high and low values of each
measure are also shown in Fig 7 to provide insight into their meaning.
As a test of the ability of our modeling methodology to replicate real tumor behavior we
studied the association between the measures obtained from the simulations and overall sur-
vival, in silico. Overall survival was defined in terms of tumor burden (see ‘Materials and
methods’). Since our model did not include therapy, typical survival times are expected to be
short. A summary of survival analysis results is shown in Fig 8, where it is clear that all mea-
sures showed statistically significant curve separation. Median differences were found to be
small, due to lack of treatment, but highly significant. These results indicate that surface regu-
larity and rim width had prognostic value in silico, as happens in real tumors [22–24, 50]. Poor
prognosis was associated with larger rim widths and lower surface regularity.
Mesoscopic simulation algorithm has good computational properties
One of the strong points of the mesoscopic simulation approach presented here is its low
computational cost, even when working with high numbers of cells. Typical simulation times
using the Julia code were a few minutes (2-6) in personal workstations and 803 grid points (Fig
9A). Although the velocity of the simulation increases with time and cell number (Fig 9B),
timescales are still acceptable. A set of 100 simulations ran from the terminal sequentially takes
around 5 hours. However, several terminals can be opened at the same time, which fastens
simulations very much. Running 100 simulations simultaneously in 10 terminals (10 sequen-
tial simulations per terminal) takes 35 minutes, with a mean execution time of 31 min per 10
simulations.
Furthermore, the model has good parallelization properties. This is due to its discretization
in spatial voxels that are updated independently and to the synchronous updating of the grid.
It it also a common feature of lattice gas models, in which parallelization has already demon-
strated increased computational performance [64]. Even though computational times are
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Fig 7. Dynamics of prognostic measures obtained from the model. A,B) Time evolution of spherical rim width and
surface regularity for 100 simulations with parameters from Table 1. The solid line is the average value and the dashed
line the standard deviation. 2D reconstructions correspond to characteristic upper and lower values of each variable.
Basal parameters, measured in hours, for each subplot are: A1) τrep = 94.2 h, τdeath = 170.8 h, τmut = 99.4 h,
rmig ¼ 0:0034 mm
2
h , A2) τ
rep = 184.9 h, τdeath = 230.1 h, τmut = 120.0 h, rmig ¼ 0:0045 mm2h , B1) τ
rep = 104.8 h, τdeath =
323.5 h, τmut = 222.7 h, rmig ¼ 0:00231 mm2h , B2) τ
rep = 158.7 h, τdeath = 54.2 h, τmut = 197.7 h, rmig ¼ 0:005 mm2h .
https://doi.org/10.1371/journal.pcbi.1008266.g007
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acceptable at this stage of modeling, there are several actions, such as increasing the lattice size,
adding biological processes or performing many runs to explore parameter regions, that may
lead to substantially longer computation times. Parallelized versions of the code will be there-
fore developed alongside these additions.
Discussion
In this paper we have presented a stochastic mesoscale simulator aimed at mimicking the
natural history of a tumor from its inception to clinically observable sizes. Many different dis-
crete simulation approaches are available to accomplish that task and shed light on different
processes in oncology [1–6]. In our case the focus was on finding a balance between
Fig 8. Prognostic measures obtained from the mathematical model recapitulate the behavior of those obtained from MRI and PET images
of GBMs. A). Kaplan-Meier curves for the population splitting using the spherical rim width taking a threshold equal to 1.93 mm. Median
survival difference between groups was 0.62 months. B). Kaplan-Meier curves for the population splitting using the surface regularity taking a
threshold equal to 0.84. Median survival difference between groups was 0.58 months.
https://doi.org/10.1371/journal.pcbi.1008266.g008
Fig 9. Elapsed time of typical model simulations. A). Elapsed simulation time for a set of 100 simulations ran independently. B). Comparison
between elapsed simulation time and tumor cell number at different time steps for a cohort of 100 simulations. Cell number does not include
dead cells.
https://doi.org/10.1371/journal.pcbi.1008266.g009
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computational complexity and biologically meaningful assumptions, allowing for the study of
a number of macroscopic features over the whole lifespan of the malignancy.
The tumor was described at the mesoscopic scale as a composition of different clonal popu-
lations at the voxel level, each of them having clone-specific characteristics that determine
their behavior. Cells grew by proliferation, migrated and diversified as a result of mutational
events that altered specific cellular processes. Death accounted for cell turnover and necrotic
core formation. These biological rules were implemented as probabilistic events, incorporating
both internal and external influences. From the point of view of simulation, these rules were
set up on a discrete three-dimensional space, following the perspective of multi-compartmen-
tal cell automaton models and matching the spatial resolution to current high-resolution med-
ical imaging standards. The three-dimensional lattice was updated synchronously, taking the
initial cell to a fully grown, spatially heterogeneous tumor. With efficiency in mind, the goal of
this setup was to minimize computational time. This makes it possible to use our modeling
framework to rapidly study different tumor dynamics scenarios and to test novel hypotheses.
The algorithm allows for further improvements in speed by adding parallelization. Special
emphasis was placed on the generation of a context of heterogeneity, competition, fixation and
natural selection, a contribution framed in the mathematical modeling of evolutionary pro-
cesses [65–67], rather than accurately parameterizing the model.
Other discrete modeling paradigms like those based on the Gillespie algorithm [68] provide
correct solution trajectories for stochastic processes but become inefficient and computation-
ally intensive when the number of events is high, due to the tau-leaping updating method.
Continuous models have been also employed in the study of evolutionary dynamics. For
example, partial differential equations can be obtained by means of mean field approximations
of the individual-level events. This analysis, however, can potentially neglect spatial correla-
tions between the locations of individuals, specially when different species or subpopulations
are taken into account [69]. In circumstances where the mean-field approximation is unsuit-
able, one needs to include information on the spatial distributions of individuals (or subpopu-
lations of those individuals), which is not a simple task from the continuous point of view. On
the contrary, this characterization can miss features that are only brought to attention by the
combination of discrete, spatial and stochastic dynamics [70].
Dynamical behavior of the tumor was first analyzed in terms of volume and radial growth.
Despite the logistic nature of each voxel’s dynamics, the whole tumor showed sustained
growth, first linear and then accelerating as a result of the diversification and interplay of the
populations, in a process that selects for more aggressive clones. Curve fitting resulted in
power law being the most accurate description, over other unbounded laws like exponential or
linear radial, pointing towards a relationship between metabolic activity, evolutionary dynam-
ics and aggressiveness [50]. The dynamics of simulated tumors changed from run to run as a
result of the stochastic nature of the model, which allowed the influence of one-off events and
parameter variability to be studied. [70]. The model provided a framework to analyze situa-
tions of clonal evolution of populations that are otherwise inferred from measurements of
mutational spectrum and proportions [19–21, 71]. Furthermore, the capacity to extend this
longitudinal simulation up to clinical sizes permits comparison of the dynamics with medical
imaging, which can in turn be used in model calibration and quantitative description [72].
This opens the door to the analysis of other features such as the expansion and size of the
necrotic core and its dependence on cell death and turnover.
Population diversification is another fundamental feature of the simulation and is analyzed
here from an evolutionary ecology point of view, with metrics like the Shannon and Simpson
indices [36]. This has already been done in heterogeneity analysis of tumors [73, 74]. The
observed oscillations in such indexes reveal the process of clonal evolution and population
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fixation, in which aggressive phenotypes progressively displace the previous clones. Heteroge-
neity decreases when this happens and is maintained when competition is active in different
regions of the tumor. This is interesting per se since heterogeneity is also spatially distributed,
meaning that there may be spatial areas of the tumor with more diversity than others. A
whole-tumor measure of diversity misses these characteristics. Three-dimensional reconstruc-
tions and exploration of the distribution of clonal populations enables the exploration of such
scenarios. Again, the possibility of understanding this process longitudinally can be a source of
hypothesis testing, particularly when combined with RNA-sequencing techniques to recon-
struct phylogenetic trees of clonal lineages for individual GBMs. Moreover, our framework
can readily incorporate the action of chemotherapeutic agents and capture the emergence of
the different processes contributing to drug resistance [75], and could also be useful to find
better chemotherapy schedules [76].
Using the model, we studied two macroscopic quantities that have been proven to show
prognostic value: surface regularity and tumor rim width [22–24]. The model simulations
were able to reproduce the behavior of these significant metrics having clinical value. Time
evolution curves of these two variables showed a progressively increasing rim width up to a sat-
uration value and a decrease in sphericity. Both can be explained as a result of the appearance
of more malignant clones that take over at the boundary, giving way to a larger infiltrative area
which manifests geometrically as a lobule protruding from the main tumor mass. This associa-
tion between degree of malignancy in terms of tumor size and morphology was confirmed by
the survival analysis of both variables.
As with any simplified dynamical model in the biological sciences, in its simplicity lie both
its virtues and its drawbacks. The downsides are the low spatial resolution at early stages due
to the coarse discretization; the absence of a microenvironment, its constituents and their
influence on cellular processes and the lack of a clear distinction of genotype and phenotype in
order to study the connection between them. The lack of these elements impedes performing a
survival analysis that takes into account all factors involved in prognosis, being limited here to
the correlation between decease and tumor burden. Also, the number of clones is specified
beforehand, in contrast to other evolutionary approaches in which the main elements emerge
from a more simplistic consideration of features (see [9] for a comprehensive review).
These drawbacks give us the future lines of work with the mesoscale simulator. A first line
of action is the addition of external components such as stromal cells, nutrients and vascula-
ture. This is of utmost importance since many therapies are critically dependent on the tumor
vasculature status. Stromal and other cell types can be added by including an additional vari-
able in each voxel, modifying the probability computation according to their influence on a
given process. Nutrients are normally modeled by means of diffusion and consumption equa-
tions, which can be integrated in discrete models by discretization [77]. Finally, vasculature
can also be considered by embedding a network into the spatial grid [78]. A second line of
action is to use the model for predicting patient’s outcome. In this regard, we are in the process
of building a database of GBM patients with genetic, geometrical, morphological and clinical
information about each patient. This kind of information is also available in online databases
such as The Cancer Genome Atlas program. These data will allow us to more precisely portrait
the genetic landscape of individual patients, adapt the parameter estimation presented here
and be able to predict relationships between phenotypic characteristics and geometrical fea-
tures. Finally, the last line of action is the implementation of treatment in the model. Treat-
ment can be included as a new event, producing cell death and inducing a deceleration on cell
division. The dynamics of this treatment-induced cell death depend on the type of therapy
considered. For example, radiotherapy would require considering a specific dose and a tumor
radiosensitivity, while chemotherapy would require addressing dose effects, half maximal
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effective concentration (EC50), and genetic/phenotypic cell traits related to drug resistance. A
more elaborated but not unaffordable approach would consist of including immune cells as a
new population, and all the interactions involved between them and tumor clonal populations,
so that immunotherapy could also be introduced in the model. Ongoing work is being done in
implementing both radiotherapy and chemotherapy treatments for glioblastoma, with temo-
zolomide as the drug of choice.
The ultimate goal of the mesoscopic model is to provide a readily usable framework not
only for hypothesis testing, but also for outcome prediction. Fitting tumors of individual
patients is admittedly a difficult task for any model, as it would require obtaining patient-spe-
cific parameter values from patient data, and available data from a single patient is usually
scarce. Rather than individual patient’s outcome prediction, our aim is to perform broad
computational studies, such as best outcome search from alternative treatment protocols, by
fitting model parameters over large sets of patients. This will help improving current treatment
schedules, which in turn may result in a better quality of life for cancer patients. We hope this
new methodology will be found to be a useful addition to the plethora of discrete simulation
approaches intended to benefit cancer patients through the tools that computational
approaches can provide.
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Conceptualization: Juan Jiménez-Sánchez, Álvaro Martı́nez-Rubio, Youness Azimzade, Juan
Belmonte-Beitia, Gabriel F. Calvo, Vı́ctor M. Pérez-Garcı́a.
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38. Vicente AMG, Pérez-Beteta J, Amo-Salas M, Pardo FJP, Martı́n MV, Valencia HS, et al. 18F-Fluoro-
choline PET/CT in the Prediction of Molecular Subtypes and Prognosis for Gliomas. Clinical Nuclear
Medicine. 2019; 44(10):e548–e558. https://doi.org/10.1097/RLU.0000000000002715
PLOS COMPUTATIONAL BIOLOGY A mesoscopic simulator to uncover heterogeneity and evolutionary dynamics in tumors
PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1008266 February 10, 2021 24 / 26
39. Hatt M, Laurent B, Fayad H, Jaouen V, Visvikis D, Le Rest CC. Tumour functional sphericity from PET
images: prognostic value in NSCLC and impact of delineation method. European Journal of Nuclear
Medicine and Molecular Imaging. 2018; 45(4):630–641. https://doi.org/10.1007/s00259-017-3865-3
40. Coroller TP, Agrawal V, Huynh E, Narayan V, Lee SW, Mak RH, et al. Radiomic-based pathological
response prediction from primary tumors and lymph nodes in NSCLC. Journal of Thoracic Oncology.
2017; 12(3):467–476. https://doi.org/10.1016/j.jtho.2016.11.2226 PMID: 27903462
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based on imaging findings in glioblastoma: Human versus Machine. Sci Rep 2019; 9:5982. https://doi.
org/10.1038/s41598-019-42326-3 PMID: 30979965
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